1. Home
  2. BMEA vs SBI Comparison

BMEA vs SBI Comparison

Compare BMEA & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.17

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.60

Market Cap

108.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
SBI
Founded
2017
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
91.1M
108.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BMEA
SBI
Price
$1.17
$7.60
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$9.83
N/A
AVG Volume (30 Days)
696.3K
61.0K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
4.52%
EPS Growth
69.19
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$7.51
52 Week High
$2.99
$8.01

Technical Indicators

Market Signals
Indicator
BMEA
SBI
Relative Strength Index (RSI) 36.91 29.88
Support Level $1.05 $7.58
Resistance Level $1.44 $7.90
Average True Range (ATR) 0.06 0.07
MACD -0.01 -0.02
Stochastic Oscillator 5.56 8.33

Price Performance

Historical Comparison
BMEA
SBI

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

Share on Social Networks: